Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply Chain: Planning & Forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029

1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered & Regional Scope
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered
1.4 Currency Considered
1.5 Stakeholders
1.6 Summary of Changes

2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Insights from Primary Experts
2.2 Market Size Estimation
2.3 Data Triangulation
2.4 Market Share Estimation
2.5 Research Assumptions
2.6 Limitations
2.6.1 Methodology-Related Limitations
2.6.2 Scope-Related Limitations
2.7 Risk Assessment

4.1 Biosimulation Market Overview
4.2 Asia-Pacific: Biosimulation Market, by Revenue Model and Country (2023)
4.3 Biosimulation Market: Geographic Growth Opportunities
4.4 Biosimulation Market: Regional Mix (2024-2029)
4.5 Biosimulation Market: Developed vs. Emerging Economies

5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing R&D Investments in Pharmaceutical and Biotechnology Industries
5.2.1.2 Growing Adoption of Biosimulation Software by Regulatory Bodies
5.2.1.3 Integration of Technologically Advanced Quantitative Systems Pharmacology (Qsp)
5.2.1.4 Need to Curtail Drug Discovery and Development Costs
5.2.1.5 Growth in Biologics and Biosimilars Markets
5.2.2 Restraints
5.2.2.1 Lack of Standardization
5.2.2.2 Data Availability and Quality
5.2.3 Opportunities
5.2.3.1 Emerging Applications
5.2.3.2 Use of Biosimulation Solutions for Pediatric Drug Development
5.2.4 Challenges
5.2.4.1 Difficulties in Matching Complexity of Biological Systems and Processes
5.2.4.2 Shortage of Biosimulation and Modeling Experts
5.3 Ecosystem Analysis
5.3.1 Software Providers
5.3.2 Pharmaceutical & Biotech Companies
5.3.3 Contract Research Organizations (Cros)
5.3.4 Regulatory Bodies
5.3.5 Academic & Research Institutions
5.4 Case Study Analysis
5.4.1 Case Study 1: Optimizing Asciminib Development Through Advanced Pbpk Modeling
5.4.2 Case Study 2: Computational Discovery of Selective Wee1 Inhibitors for Cancer
5.4.3 Case Study 3: Efficient Clinical Trial Utilizing Scale Management Expertise
5.5 Value Chain Analysis
5.6 Porter's Five Forces Analysis
5.6.1 Bargaining Power of Suppliers
5.6.2 Bargaining Power of Buyers
5.6.3 Threat of Substitutes
5.6.4 Threat of New Entrants
5.6.5 Intensity of Competitive Rivalry
5.7 Regulatory Analysis
5.7.1 Regulatory Landscape
5.7.1.1 North America
5.7.1.2 Europe
5.7.1.3 Asia-Pacific
5.7.1.4 Latin America
5.7.1.5 Middle East & Africa
5.7.2 Regulatory Bodies, Government Agencies, and Other Organizations
5.8 Patent Analysis
5.8.1 Patent Publication Trends for Biosimulation
5.8.2 Jurisdiction and Top Applicant Analysis
5.9 Technology Analysis
5.9.1 Key Technologies
5.9.1.1 Mathematical Modeling
5.9.1.2 Software Platforms
5.9.1.3 Quantitative Systems Pharmacology (Qsp)
5.9.2 Complementary Technologies
5.9.2.1 Data Analytics
5.9.2.2 Machine Learning and AI
5.9.3 Adjacent Technologies
5.9.3.1 In Silico Trials
5.10 Industry Trends
5.10.1 Discovery of Biomarkers
5.10.2 Adoption in Personalized Medicine
5.11 Pricing Analysis
5.11.1 Indicative Pricing Analysis of Key Players, by Offering, 2023
5.11.2 Average Selling Price Trend, by Region (Qualitative)
5.12 Key Conferences & Events, 2024-2025
5.13 Key Stakeholders & Buying Criteria
5.13.1 Buying Criteria
5.14 Trends & Disruptions Impacting Customers’ Businesses
5.15 End-user Analysis
5.15.1 Unmet Needs
5.15.2 End-user Expectations
5.16 Investment & Funding Scenario
5.17 Impact of AI/Gen AI on Biosimulation Market
5.17.1 Key Use Cases
5.17.2 Impact of AI/Gen AI on Interconnected and Adjacent Ecosystems
5.17.2.1 Case Study
5.17.2.2 Bioinformatics Market
5.17.2.3 Drug Discovery Services Market
5.17.2.4 Drug Discovery Informatics Market
5.17.3 User Readiness & Impact Assessment
5.17.3.1 User Readiness
5.17.3.1.1 Pharmaceutical & Biotechnology Companies
5.17.3.1.2 Contract Research Organizations
5.17.3.2 Impact Assessment
5.17.3.2.1 User A: Pharmaceutical & Biotechnology Companies
5.17.3.2.1.1 Implementation
5.17.3.2.1.2 Impact
5.17.3.2.2 User B: Academic & Research Institutes
5.17.3.2.2.1 Implementation
5.17.3.2.2.2 Impact

6.1 Introduction
6.2 Software
6.2.1 Standalone Modules
6.2.1.1 Molecular Modeling & Simulation Software
6.2.1.1.1 Growing Importance of Molecular Modeling & Simulation in Drug Discovery and Development to Accelerate Market Growth
6.2.1.2 Pk/Pd Modeling & Simulation Software
6.2.1.2.1 Pivotal Role in Early Drug Development Phase to Boost Market Growth
6.2.1.3 Pbpk Modeling & Simulation Software
6.2.1.3.1 Widespread Use by Regulatory Bodies to Drive Pbpk Modeling & Simulation Software Market
6.2.1.4 Toxicity Prediction Software
6.2.1.4.1 Pressing Need for Toxicity Prediction in Drug Discovery and Development is Driving the Market
6.2.1.5 Clinical Trial Simulation Software
6.2.1.5.1 High Failure Rate of Clinical Trials to Accelerate Growth
6.2.1.6 Other Biosimulation Software
6.2.2 Integrated Software Suites/Platforms
6.2.2.1 Need for Efficient R&D Tools to Accelerate Growth of Integrated Platforms
6.3 Services
6.3.1 Consulting & Advisory
6.3.1.1 Need to Focus on Core Competencies to Drive Need for Consulting & Advisory Services
6.3.2 Implementation, Training, and Support
6.3.2.1 Need for Well-Trained Professionals and Experts to Accelerate Market Growth
6.3.3 Data Analysis & Interpretation
6.3.3.1 Accurate and Precise Interpretation of Data to Drive Need for Data Analysis & Interpretation Services

7.1 Introduction
7.2 Drug Discovery
7.2.1 Target Identification & Validation
7.2.1.1 Need for Identification of Optimal Targets in Drug Discovery to Drive Market
7.2.2 Lead Identification & Optimization
7.2.2.1 Crucial Role in Facilitating Viable Drug Discovery to Accelerate Market Growth
7.3 Drug Development
7.3.1 Preclinical Testing
7.3.1.1 Pk/Pd
7.3.1.1.1 Critical Role of Pk/Pd Studies in Drug Development to Drive Market
7.3.1.2 Adme/Toxicology
7.3.1.2.1 Growing Role in Selection of Potent Drug Molecules to Boost Market Growth
7.3.2 Clinical Trials
7.3.2.1 Phase I
7.3.2.1.1 Growing Need to Ease Decision-Making Process to Drive Segmental Growth
7.3.2.2 Phase II
7.3.2.2.1 Efficiency in Dose Assessment and Product Efficacy to Drive Growth
7.3.2.3 Phase III
7.3.2.3.1 Need to Curtail Large Costs Involved in Trials to Propel Demand
7.3.2.4 Phase IV/Post-Marketing Surveillance
7.3.2.4.1 Ability to Assist Researchers in Process Innovation and Decision Support to Drive Adoption
7.4 Disease Modeling
7.4.1 Capability to Predict Disease Dynamics and Inform Therapeutic Strategies to Drive Market Growth
7.5 Manufacturing & Supply Chain Management
7.5.1 Production Planning & Optimization
7.5.1.1 Need for Proper Production Planning and Execution to Drive Market Growth
7.5.2 Quality Control & Process Monitoring
7.5.2.1 Adherence to Maintaining Product Quality to Fuel Market Growth
7.5.3 Demand Forecasting & Inventory Management
7.5.3.1 Need to Forecast Demand Effectively to Drive Market Growth
7.5.4 Risk Management & Contingency Planning
7.5.4.1 Need to Maintain Operational Continuity to Support Market Growth
7.5.5 Other Manufacturing & Supply Chain Management Applications
7.6 Other Applications

8.1 Introduction
8.2 Oncology
8.2.1 High Prevalence of Cancer and Shortage of Effective Cancer Drugs to Drive Market Growth
8.3 Cardiovascular Diseases
8.3.1 Rising Need for Drugs to Treat Cardiovascular Diseases to Boost Market
8.4 Neurological Disorders
8.4.1 Need to Boost Drug Discovery and Development for Neurological Disorders to Support Market Growth
8.5 Infectious Diseases
8.5.1 Rising Epidemic Outbreaks to Boost Drug Discovery Activity
8.6 Other Therapeutic Areas

9.1 Introduction
9.2 License-based Models
9.2.1 License-based Models to Account for Largest Share of Market
9.3 Subscription-based Models
9.3.1 Subscription-based Models to Register Highest Growth Rate During Forecast Period
9.4 Service-based Models
9.4.1 Specialized Simulation Expertise with Service-based Models to Support Adoption
9.5 Pay-Per-Use Models
9.5.1 Rising Demand for Flexible Biosimulation Solutions Without Upfront Costs to Support Market Growth

10.1 Introduction
10.2 On-Premise Models
10.2.1 Optimal Control on Deployment and Data Backup to Support Market Uptake
10.3 Cloud-based Models
10.3.1 Cloud-based Model to Experience Highest Growth Rate During Forecast Period
10.4 Hybrid Models
10.4.1 Balanced Capabilities of Hybrid Biosimulation Models to Accelerate Adoption

11.1 Introduction
11.2 Pharmaceutical & Biotechnology Companies
11.2.1 Increasing R&D Expenditure for Drug Discovery and Development to Drive Market
11.3 Contract Research Organizations
11.3.1 Rising Outsourcing of Clinical Trial Activities to Cros by Pharmaceutical Companies to Drive Market
11.4 Academic & Research Institutes
11.4.1 Favorable Government Support for Research to Support Market Growth
11.5 Regulatory Bodies
11.5.1 Growing Usage of Biosimulation Software for Clinical Trial Efficacy to Propel Market Growth
11.6 Other End-users

12.1 Introduction
12.2 North America
12.2.1 Macroeconomic Outlook for North America
12.2.2 US
12.2.2.1 Rising Government Funding for Pharmaceutical R&D to Drive Market
12.2.3 Canada
12.2.3.1 Increasing Funding by Canadian Government in Healthcare to Drive Market
12.3 Europe
12.3.1 Macroeconomic Outlook for Europe
12.3.2 Germany
12.3.2.1 High Number of Sponsored Clinical Trials to Drive Uptake of Biosimulation
12.3.3 UK
12.3.3.1 Investments by Pharmaceutical Sponsors for Drug Discovery Services to Boost Market
12.3.4 France
12.3.4.1 Growing R&D Pipeline for Clinical Trials to Drive Market
12.3.5 Italy
12.3.5.1 Increasing Government Funds and Favorable Regulatory Scenarios to Fuel Uptake
12.3.6 Spain
12.3.6.1 Established Network of Research Centers to Propel Market
12.3.7 Rest of Europe
12.4 Asia-Pacific
12.4.1 Macroeconomic Outlook for Asia-Pacific
12.4.2 China
12.4.2.1 Low Cost of Drug Development and Large Pharmaceutical R&D Base to Drive Market
12.4.3 India
12.4.3.1 Growing Pharmaceutical Industry to Fuel Uptake of Biosimulation
12.4.4 Japan
12.4.4.1 Established Drug Development Infrastructure and Biomedical Research Capabilities to Support Market Growth
12.4.5 Rest of Asia-Pacific
12.5 Latin America
12.5.1 Macroeconomic Outlook for Latin America
12.5.2 Brazil
12.5.2.1 Advancing Biosimulation in Region to Support Market Growth
12.5.3 Mexico
12.5.3.1 Government Initiatives to Enhance Digital Health to Propel Market Growth
12.5.4 Rest of Latin America
12.6 Middle East & Africa
12.6.1 Macroeconomic Outlook for Middle East & Africa
12.6.2 GCC Countries
12.6.2.1 Increase in Healthcare Investments to Support Market Growth
12.6.3 Rest of Middle East & Africa

13.1 Introduction
13.2 Key Player Strategy/Right to Win
13.2.1 Overview of Strategies Adopted by Players in Biosimulation Market
13.3 Revenue Analysis, 2019-2023
13.4 Market Share Analysis, 2023
13.4.1 Certara, USA (US)
13.4.2 Dassault Systèmes (France)
13.4.3 Schrödinger, Inc. (US)
13.4.4 Simulations Plus (US)
13.4.5 Advanced Chemistry Development, Inc. (Canada)
13.5 Ranking of Key Market Players
13.6 Company Evaluation Matrix: Key Players, 2023
13.6.1 Stars
13.6.2 Emerging Leaders
13.6.3 Pervasive Players
13.6.4 Participants
13.6.5 Company Footprint: Key Players, 2023
13.6.5.1 Company Footprint
13.6.5.2 Offering Footprint
13.6.5.3 Application Footprint
13.6.5.4 End-user Footprint
13.6.5.5 Region Footprint
13.7 Company Evaluation Matrix: Start-Up/SMEs, 2023
13.7.1 Progressive Companies
13.7.2 Responsive Companies
13.7.3 Dynamic Companies
13.7.4 Starting Blocks
13.7.5 Competitive Benchmarking: Startups/SMEs, 2023
13.8 Company Evaluation & Financial Metrics
13.9 Brand/Product Comparison
13.10 Competitive Scenario
13.10.1 Product Launches & Enhancements
13.10.2 Deals
13.10.3 Expansions
13.10.4 Other Developments

14.1 Key Players
14.1.1 Certara, USA
14.1.1.1 Business Overview
14.1.1.2 Products & Services Offered
14.1.1.3 Recent Developments
14.1.1.3.1 Product Launches & Enhancements
14.1.1.3.2 Deals
14.1.1.4 Analyst's View
14.1.1.4.1 Right to Win
14.1.1.4.2 Strategic Choices
14.1.1.4.3 Weaknesses & Competitive Threats
14.1.2 Dassault Systèmes
14.1.2.1 Business Overview
14.1.2.2 Products & Services Offered
14.1.2.3 Recent Developments
14.1.2.3.1 Deals
14.1.2.4 Analyst's View
14.1.2.4.1 Right to Win
14.1.2.4.2 Strategic Choices
14.1.2.4.3 Weaknesses & Competitive Threats
14.1.3 Schrödinger, Inc.
14.1.3.1 Business Overview
14.1.3.2 Products & Services Offered
14.1.3.3 Recent Developments
14.1.3.3.1 Deals
14.1.3.4 Analyst's View
14.1.3.4.1 Right to Win
14.1.3.4.2 Strategic Choices
14.1.3.4.3 Weaknesses & Competitive Threats
14.1.4 Simulations Plus
14.1.4.1 Business Overview
14.1.4.2 Products & Services Offered
14.1.4.3 Recent Developments
14.1.4.3.1 Product Launches & Enhancements
14.1.4.3.2 Deals
14.1.4.3.3 Other Developments
14.1.5 Advanced Chemistry Development, Inc.
14.1.5.1 Business Overview
14.1.5.2 Products & Services Offered
14.1.5.3 Recent Developments
14.1.5.3.1 Product Launches & Enhancements
14.1.5.3.2 Deals
14.1.6 Chemical Computing Group Ulc
14.1.6.1 Business Overview
14.1.6.2 Products & Services Offered
14.1.6.3 Recent Developments
14.1.6.3.1 Deals
14.1.7 Rosa & Co. LLC
14.1.7.1 Business Overview
14.1.7.2 Products & Services Offered
14.1.8 Genedata AG (A Danaher Company)
14.1.8.1 Business Overview
14.1.8.2 Products & Services Offered
14.1.8.3 Recent Developments
14.1.8.3.1 Product Launches & Enhancements
14.1.8.3.2 Deals
14.1.9 Physiomics PLC
14.1.9.1 Business Overview
14.1.9.2 Products & Services Offered
14.1.9.3 Recent Developments
14.1.9.3.1 Deals
14.1.10 In Silico Biosciences
14.1.10.1 Business Overview
14.1.10.2 Products & Services Offered
14.1.11 Allucent
14.1.11.1 Business Overview
14.1.11.2 Products & Services Offered
14.1.11.3 Recent Developments
14.1.11.3.1 Deals
14.1.11.3.2 Expansions
14.1.12 Openeye, Cadence Molecular Sciences
14.1.12.1 Business Overview
14.1.12.2 Products & Services Offered
14.1.12.3 Recent Developments
14.1.12.3.1 Product Enhancements
14.1.12.3.2 Deals
14.1.12.3.3 Expansions
14.1.13 Cellworks Group, Inc.
14.1.13.1 Business Overview
14.1.13.2 Products & Services Offered
14.1.13.3 Recent Developments
14.1.13.3.1 Expansions
14.1.14 Verisim Life
14.1.14.1 Business Overview
14.1.14.2 Products & Services Offered
14.1.14.3 Recent Developments
14.1.14.3.1 Deals
14.1.14.3.2 Other Developments
14.1.15 Netabolics
14.1.15.1 Business Overview
14.1.15.2 Products & Services Offered
14.1.16 Charnwood Discovery
14.1.16.1 Business Overview
14.1.16.2 Products & Services Offered
14.1.16.3 Recent Developments
14.1.16.3.1 Deals
14.1.17 The Mathworks, Inc.
14.1.17.1 Business Overview
14.1.17.2 Products & Services Offered
14.1.17.3 Recent Developments
14.1.17.3.1 Product Enhancements
14.1.18 Ansys, Inc.
14.1.18.1 Business Overview
14.1.18.2 Products & Services Offered
14.2 Start-Up/SME Players
14.2.1 Instem Group of Companies
14.2.2 Insilico Medicine
14.2.3 Scm - Software Chemistry & Materials
14.2.4 Biosymetrics, Inc.
14.2.5 Atomwise Inc.
14.2.6 Insitro
14.2.7 Clinithink

15.1 Discussion Guide
15.2 Knowledgestore: The Subscription Portal
15.3 Customization Options

Table 1 Biosimulation Market: Role of Companies in Ecosystem
Table 2 Biosimulation Market: Porter's Five Forces
Table 3 North America: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 4 Europe: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 5 Asia-Pacific: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 6 Latin America: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 7 Middle East & Africa: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 8 Indicative Pricing Analysis of Key Players, by Offering
Table 9 Biosimulation Market: Key Conferences and Events, 2024-2025
Table 10 Influence of Stakeholders on Buying Process of Top 3 End-users (%)
Table 11 Key Buying Criteria for Top 3 End-users
Table 12 Unmet Needs in Biosimulation Market
Table 13 End-user Expectations in Biosimulation Market
Table 14 Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 15 Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 16 Biosimulation Software Market, by Country, 2022-2029 (USD Million)
Table 17 Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 18 Biosimulation Market for Standalone Modules, by Country, 2022-2029 (USD Million)
Table 19 Biosimulation Market for Molecular Modeling & Simulation Software, by Country, 2022-2029 (USD Million)
Table 20 Biosimulation Market for Pk/Pd Modeling & Simulation Software, by Country, 2022-2029 (USD Million)
Table 21 Biosimulation Market for Pbpk Modeling & Simulation Software, by Country, 2022-2029 (USD Million)
Table 22 Biosimulation Market for Toxicity Prediction Software, by Country, 2022-2029 (USD Million)
Table 23 Biosimulation Market for Clinical Trial Simulation Software, by Country, 2022-2029 (USD Million)
Table 24 Biosimulation Market for Other Biosimulation Software, by Country, 2022-2029 (USD Million)
Table 25 Biosimulation Market for Integrated Software Suites/Platforms, by Country, 2022-2029 (USD Million)
Table 26 Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 27 Biosimulation Services Market, by Country, 2022-2029 (USD Million)
Table 28 Biosimulation Market for Consulting & Advisory Services, by Country, 2022-2029 (USD Million)
Table 29 Biosimulation Market for Implementation, Training, and Support Services, by Country, 2022-2029 (USD Million)
Table 30 Biosimulation Market for Data Analysis & Interpretation Services, by Country, 2022-2029 (USD Million)
Table 31 Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 32 Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 33 Biosimulation Market for Drug Discovery Applications, by Country, 2022-2029 (USD Million)
Table 34 Biosimulation Market for Target Identification & Validation, by Country, 2022-2029 (USD Million)
Table 35 Biosimulation Market for Lead Identification & Optimization, by Country, 2022-2029 (USD Million)
Table 36 Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 37 Biosimulation Market for Drug Development Applications, by Country, 2022-2029 (USD Million)
Table 38 Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 39 Biosimulation Market for Preclinical Testing, by Country, 2022-2029 (USD Million)
Table 40 Biosimulation Market for Pk/Pd, by Country, 2022-2029 (USD Million)
Table 41 Biosimulation Market for Adme/Toxicology, by Country, 2022-2029 (USD Million)
Table 42 Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 43 Biosimulation Market for Clinical Trials, by Country, 2022-2029 (USD Million)
Table 44 Biosimulation Market for Phase I Clinical Trials, by Country, 2022-2029 (USD Million)
Table 45 Biosimulation Market for Phase II Clinical Trials, by Country, 2022-2029 (USD Million)
Table 46 Biosimulation Market for Phase III Clinical Trials, by Country, 2022-2029 (USD Million)
Table 47 Biosimulation Market for Phase IV/Post-Marketing Surveillance, by Country, 2022-2029 (USD Million)
Table 48 Biosimulation Market for Disease Modeling Applications, by Country, 2022-2029 (USD Million)
Table 49 Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 50 Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Country, 2022-2029 (USD Million)
Table 51 Biosimulation Market for Production Planning & Optimization, by Country, 2022-2029 (USD Million)
Table 52 Biosimulation Market for Quality Control & Process Monitoring, by Country, 2022-2029 (USD Million)
Table 53 Biosimulation Market for Demand Forecasting & Inventory Management, by Country, 2022-2029 (USD Million)
Table 54 Biosimulation Market for Risk Management & Contingency Planning, by Country, 2022-2029 (USD Million)
Table 55 Biosimulation Market for Other Manufacturing & Supply Chain Management Applications, by Country, 2022-2029 (USD Million)
Table 56 Biosimulation Market for Other Applications, by Country, 2022-2029 (USD Million)
Table 57 Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 58 Biosimulation Market for Oncology, by Country, 2022-2029 (USD Million)
Table 59 Biosimulation Market for Cardiovascular Diseases, by Country, 2022-2029 (USD Million)
Table 60 Biosimulation Market for Neurological Disorders, by Country, 2022-2029 (USD Million)
Table 61 Biosimulation Market for Infectious Diseases, by Country, 2022-2029 (USD Million)
Table 62 Biosimulation Market for Other Therapeutic Areas, by Country, 2022-2029 (USD Million)
Table 63 Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 64 Biosimulation Market for License-based Models, by Country, 2022-2029 (USD Million)
Table 65 Biosimulation Market for Subscription-based Models, by Country, 2022-2029 (USD Million)
Table 66 Biosimulation Market for Service-based Models, by Country, 2022-2029 (USD Million)
Table 67 Biosimulation Market for Pay-Per-Use Models, by Country, 2022-2029 (USD Million)
Table 68 Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 69 Biosimulation Market for On-Premise Models, by Country, 2022-2029 (USD Million)
Table 70 Biosimulation Market for Cloud-based Models, by Country, 2022-2029 (USD Million)
Table 71 Biosimulation Market for Hybrid Models, by Country, 2022-2029 (USD Million)
Table 72 Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 73 Biosimulation Market for Pharmaceutical & Biotechnology Companies, by Country, 2022-2029 (USD Million)
Table 74 Biosimulation Market for Contract Research Organizations, by Country, 2022-2029 (USD Million)
Table 75 Biosimulation Market for Academic & Research Institutes, by Country, 2022-2029 (USD Million)
Table 76 Biosimulation Market for Regulatory Bodies, by Country, 2022-2029 (USD Million)
Table 77 Biosimulation Market for Other End-users, by Country, 2022-2029 (USD Million)
Table 78 Biosimulation Market, by Region, 2022-2029 (USD Million)
Table 79 North America: Biosimulation Market, by Country, 2022-2029 (USD Million)
Table 80 North America: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 81 North America: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 82 North America: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 83 North America: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 84 North America: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 85 North America: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 86 North America: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 87 North America: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 88 North America: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 89 North America: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 90 North America: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 91 North America: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 92 North America: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 93 North America: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 94 US: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 95 US: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 96 US: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 97 US: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 98 US: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 99 US: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 100 US: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 101 US: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 102 US: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 103 US: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 104 US: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 105 US: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 106 US: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 107 US: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 108 Canada: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 109 Canada: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 110 Canada: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 111 Canada: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 112 Canada: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 113 Canada: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 114 Canada: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 115 Canada: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 116 Canada: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 117 Canada: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 118 Canada: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 119 Canada: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 120 Canada: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 121 Canada: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 122 Europe: Biosimulation Market, by Country, 2022-2029 (USD Million)
Table 123 Europe: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 124 Europe: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 125 Europe: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 126 Europe: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 127 Europe: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 128 Europe: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 129 Europe: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 130 Europe: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 131 Europe: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 132 Europe: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 133 Europe: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 134 Europe: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 135 Europe: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 136 Europe: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 137 Germany: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 138 Germany: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 139 Germany: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 140 Germany: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 141 Germany: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 142 Germany: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 143 Germany: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 144 Germany: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 145 Germany: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 146 Germany: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 147 Germany: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 148 Germany: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 149 Germany: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 150 Germany: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 151 UK: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 152 UK: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 153 UK: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 154 UK: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 155 UK: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 156 UK: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 157 UK: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 158 UK: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 159 UK: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 160 UK: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 161 UK: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 162 UK: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 163 UK: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 164 UK: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 165 France: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 166 France: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 167 France: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 168 France: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 169 France: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 170 France: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 171 France: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 172 France: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 173 France: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 174 France: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 175 France: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 176 France: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 177 France: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 178 France: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 179 Italy: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 180 Italy: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 181 Italy: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 182 Italy: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 183 Italy: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 184 Italy: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 185 Italy: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 186 Italy: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 187 Italy: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 188 Italy: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 189 Italy: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 190 Italy: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 191 Italy: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 192 Italy: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 193 Spain: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 194 Spain: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 195 Spain: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 196 Spain: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 197 Spain: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 198 Spain: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 199 Spain: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 200 Spain: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 201 Spain: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 202 Spain: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 203 Spain: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 204 Spain: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 205 Spain: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 206 Spain: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 207 Rest of Europe: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 208 Rest of Europe: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 209 Rest of Europe: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 210 Rest of Europe: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 211 Rest of Europe: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 212 Rest of Europe: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 213 Rest of Europe: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 214 Rest of Europe: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 215 Rest of Europe: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 216 Rest of Europe: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 217 Rest of Europe: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 218 Rest of Europe: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 219 Rest of Europe: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 220 Rest of Europe: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 221 Asia-Pacific: Biosimulation Market, by Country, 2022-2029 (USD Million)
Table 222 Asia-Pacific: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 223 Asia-Pacific: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 224 Asia-Pacific: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 225 Asia-Pacific: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 226 Asia-Pacific: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 227 Asia-Pacific: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 228 Asia-Pacific: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 229 Asia-Pacific: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 230 Asia-Pacific: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 231 Asia-Pacific: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 232 Asia-Pacific: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 233 Asia-Pacific: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 234 Asia-Pacific: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 235 Asia-Pacific: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 236 China: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 237 China: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 238 China: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 239 China: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 240 China: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 241 China: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 242 China: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 243 China: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 244 China: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 245 China: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 246 China: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 247 China: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 248 China: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 249 China: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 250 India: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 251 India: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 252 India: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 253 India: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 254 India: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 255 India: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 256 India: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 257 India: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 258 India: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 259 India: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 260 India: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 261 India: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 262 India: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 263 India: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 264 Japan: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 265 Japan: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 266 Japan: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 267 Japan: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 268 Japan: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 269 Japan: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 270 Japan: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 271 Japan: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 272 Japan: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 273 Japan: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 274 Japan: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 275 Japan: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 276 Japan: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 277 Japan: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 278 Rest of Asia-Pacific: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 279 Rest of Asia-Pacific: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 280 Rest of Asia-Pacific: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 281 Rest of Asia-Pacific: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 282 Rest of Asia-Pacific: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 283 Rest of Asia-Pacific: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 284 Rest of Asia-Pacific: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 285 Rest of Asia-Pacific: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 286 Rest of Asia-Pacific: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 287 Rest of Asia-Pacific: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 288 Rest of Asia-Pacific: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 289 Rest of Asia-Pacific: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 290 Rest of Asia-Pacific: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 291 Rest of Asia-Pacific: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 292 Latin America: Biosimulation Market, by Country, 2022-2029 (USD Million)
Table 293 Latin America: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 294 Latin America: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 295 Latin America: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 296 Latin America: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 297 Latin America: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 298 Latin America: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 299 Latin America: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 300 Latin America: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 301 Latin America: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 302 Latin America: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 303 Latin America: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 304 Latin America: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 305 Latin America: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 306 Latin America: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 307 Brazil: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 308 Brazil: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 309 Brazil: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 310 Brazil: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 311 Brazil: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 312 Brazil: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 313 Brazil: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 314 Brazil: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 315 Brazil: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 316 Brazil: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 317 Brazil: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 318 Brazil: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 319 Brazil: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 320 Brazil: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 321 Mexico: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 322 Mexico: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 323 Mexico: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 324 Mexico: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 325 Mexico: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 326 Mexico: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 327 Mexico: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 328 Mexico: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 329 Mexico: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 330 Mexico: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 331 Mexico: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 332 Mexico: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 333 Mexico: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 334 Mexico: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 335 Rest of Latin America: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 336 Rest of Latin America: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 337 Rest of Latin America: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 338 Rest of Latin America: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 339 Rest of Latin America: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 340 Rest of Latin America: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 341 Rest of Latin America: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 342 Rest of Latin America: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 343 Rest of Latin America: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 344 Rest of Latin America: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 345 Rest of Latin America: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 346 Rest of Latin America: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 347 Rest of Latin America: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 348 Rest of Latin America: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 349 Middle East & Africa: Biosimulation Market, by Country, 2022-2029 (USD Million)
Table 350 Middle East & Africa: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 351 Middle East & Africa: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 352 Middle East & Africa: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 353 Middle East & Africa: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 354 Middle East & Africa: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 355 Middle East & Africa: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 356 Middle East & Africa: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 357 Middle East & Africa: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 358 Middle East & Africa: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 359 Middle East & Africa: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 360 Middle East & Africa: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 361 Middle East & Africa: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 362 Middle East & Africa: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 363 Middle East & Africa: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 364 GCC Countries: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 365 GCC Countries: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 366 GCC Countries: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 367 GCC Countries: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 368 GCC Countries: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 369 GCC Countries: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 370 GCC Countries: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 371 GCC Countries: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 372 GCC Countries: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 373 GCC Countries: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 374 GCC Countries: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 375 GCC Countries: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 376 GCC Countries: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 377 GCC Countries: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 378 Rest of Middle East & Africa: Biosimulation Market, by Offering, 2022-2029 (USD Million)
Table 379 Rest of Middle East & Africa: Biosimulation Software Market, by Type, 2022-2029 (USD Million)
Table 380 Rest of Middle East & Africa: Biosimulation Market for Standalone Modules, by Type, 2022-2029 (USD Million)
Table 381 Rest of Middle East & Africa: Biosimulation Services Market, by Type, 2022-2029 (USD Million)
Table 382 Rest of Middle East & Africa: Biosimulation Market, by Application, 2022-2029 (USD Million)
Table 383 Rest of Middle East & Africa: Biosimulation Market for Drug Discovery Applications, by Type, 2022-2029 (USD Million)
Table 384 Rest of Middle East & Africa: Biosimulation Market for Drug Development Applications, by Type, 2022-2029 (USD Million)
Table 385 Rest of Middle East & Africa: Biosimulation Market for Preclinical Testing, by Type, 2022-2029 (USD Million)
Table 386 Rest of Middle East & Africa: Biosimulation Market for Clinical Trials, by Type, 2022-2029 (USD Million)
Table 387 Rest of Middle East & Africa: Biosimulation Market for Manufacturing & Supply Chain Management Applications, by Type, 2022-2029 (USD Million)
Table 388 Rest of Middle East & Africa: Biosimulation Market, by Therapeutic Area, 2022-2029 (USD Million)
Table 389 Rest of Middle East & Africa: Biosimulation Market, by Revenue Model, 2022-2029 (USD Million)
Table 390 Rest of Middle East & Africa North America: Biosimulation Market, by Deployment Model, 2022-2029 (USD Million)
Table 391 Rest of Middle East & Africa: Biosimulation Market, by End-user, 2022-2029 (USD Million)
Table 392 Overview of Strategies Adopted by Key Players in Biosimulation Market
Table 393 Biosimulation Market: Degree of Competition
Table 394 Biosimulation Market: Offering Footprint
Table 395 Biosimulation Market: Application Footprint
Table 396 Biosimulation Market: End-user Footprint
Table 397 Biosimulation Market: Region Footprint
Table 398 Biosimulation Market: Detailed List of Key Start-Ups/SMEs
Table 399 Biosimulation Market: Competitive Benchmarking of Key Emerging Players/Startups
Table 400 Biosimulation Market: Product Launches & Enhancements, January 2021-October 2024
Table 401 Biosimulation Market: Deals, January 2021-October 2024
Table 402 Biosimulation Market: Expansions, January 2021-October 2024
Table 403 Biosimulation Market: Other Developments, January 2021-October 2024
Table 404 Certara, USA: Company Overview
Table 405 Certara, USA: Products & Services Offered
Table 406 Certara, USA: Product Launches & Enhancements, January 2021-October 2024
Table 407 Certara, USA: Deals, January 2021-October 2024
Table 408 Dassault Systèmes: Company Overview
Table 409 Dassault Systèmes: Products & Services Offered
Table 410 Dassault Systèmes: Deals, January 2021-June 2024
Table 411 Schrödinger, Inc.: Company Overview
Table 412 Schrödinger, Inc.: Products & Services Offered
Table 413 Schrödinger, Inc.: Deals, January 2021-October 2024
Table 414 Simulations Plus: Company Overview
Table 415 Simulations Plus: Products & Services Offered
Table 416 Simulations Plus: Product Launches & Enhancements, January 2021-October 2024
Table 417 Simulations Plus: Deals, January 2021-October 2024
Table 418 Simulations Plus: Other Developments, January 2021-October 2024
Table 419 Advanced Chemistry Development, Inc.: Company Overview
Table 420 Advanced Chemistry Development, Inc.: Products & Services Offered
Table 421 Advanced Chemistry Development, Inc.: Product Launches & Enhancements, January 2021-October 2024
Table 422 Advanced Chemistry Development, Inc.: Deals, January 2021-October 2024
Table 423 Chemical Computing Group Ulc: Company Overview
Table 424 Chemical Computing Group Ulc: Products & Services Offered
Table 425 Chemical Computing Group Ulc: Deals, January 2021-October 2024
Table 426 Rosa & Co. LLC: Company Overview
Table 427 Rosa & Co. LLC: Products & Services Offered
Table 428 Genedata AG (A Danaher Company): Company Overview
Table 429 Genedata AG (A Danaher Company): Products & Services Offered
Table 430 Genedata AG (A Danaher Company): Product Launches & Enhancements, January 2021-October 2024
Table 431 Genedata AG (A Danaher Company): Deals, January 2021-October 2024
Table 432 Physiomics PLC: Company Overview
Table 433 Physiomics PLC: Products & Services Offered
Table 434 Physiomics PLC: Deals, January 2021-October 2024
Table 435 In Silico Biosciences: Company Overview
Table 436 In Silico Biosciences: Products & Services Offered
Table 437 Allucent: Company Overview
Table 438 Allucent: Products & Services Offered
Table 439 Allucent: Deals, January 2021-October 2024
Table 440 Allucent: Expansions, January 2021-October 2024
Table 441 Openeye, Cadence Molecular Sciences: Company Overview
Table 442 Openeye, Cadence Molecular Sciences: Products & Services Offered
Table 443 Openeye, Cadence Molecular Sciences: Product Enhancements, January 2021-October 2024
Table 444 Openeye, Cadence Molecular Sciences: Deals, January 2021-October 2024
Table 445 Openeye, Cadence Molecular Sciences: Expansions, January 2021-October 2024
Table 446 Cellworks Group, Inc.: Company Overview
Table 447 Cellworks Group, Inc.: Products & Services Offered
Table 448 Cellworks Group, Inc.: Expansions, January 2021-October 2024
Table 449 Verisim Life: Company Overview
Table 450 Verisim Life: Products & Services Offered
Table 451 Verisim Life: Deals, January 2021-October 2024
Table 452 Verisim Life: Other Developments, January 2021-October 2024
Table 453 Netabolics: Company Overview
Table 454 Netabolics: Products & Services Offered
Table 455 Charnwood Discovery: Company Overview
Table 456 Charnwood Discovery: Products & Services Offered
Table 457 Charnwood Discovery: Deals, January 2021-October 2024
Table 458 The Mathworks, Inc.: Company Overview
Table 459 The Mathworks, Inc.: Products & Services Offered
Table 460 The Mathworks, Inc.: Product Enhancements, January 2021-October 2024
Table 461 Ansys, Inc.: Company Overview
Table 462 Ansys, Inc.: Products & Services Offered

Figure 1 Biosimulation Market Segmentation & Regional Scope
Figure 2 Research Design
Figure 3 Primary Sources
Figure 4 Breakdown of Primary Interviews (Demand Side): by Company Type, Designation, and Region
Figure 5 Market Size Estimation: Revenue Share Analysis
Figure 6 Top-Down Approach
Figure 7 CAGR Projections, 2024-2029
Figure 8 CAGR Projections: Supply-Side Analysis
Figure 9 Data Triangulation
Figure 10 Biosimulation Market, by Offering, 2024 vs. 2029 (USD Million)
Figure 11 Biosimulation Market, by Application, 2024 vs. 2029 (USD Million)
Figure 12 Biosimulation Market, by Therapeutic Area, 2024 vs. 2029 (USD Million)
Figure 13 Biosimulation Market, by Revenue Model, 2024 vs. 2029 (USD Million)
Figure 14 Biosimulation Market, by Deployment Model, 2024 vs. 2029 (USD Million)
Figure 15 Biosimulation Market, by End-user, 2024 vs. 2029 (USD Million)
Figure 16 Geographic Snapshot of Biosimulation Market
Figure 17 Increasing R&D Expenditure on Drug Discovery & Development by Pharmaceutical & Biotechnology Companies to Drive Market
Figure 18 China Dominated Market in Asia-Pacific in 2023
Figure 19 India to Register Highest Growth Rate During Forecast Period
Figure 20 North America to Dominate Biosimulation Market During Forecast Period
Figure 21 Emerging Economies to Register Higher Growth Rates During Forecast Period
Figure 22 Biosimulation Market: Drivers, Restraints, Opportunities, and Challenges
Figure 23 Biosimulation Market: Ecosystem Analysis
Figure 24 Biosimulation Market: Value Chain Analysis
Figure 25 Biosimulation Market: Porter's Five Forces Analysis
Figure 26 Patent Publication Trends in Biosimulation Market, 2015-2024
Figure 27 Biosimulation Market: Patent Analysis, January 2015-September 2024
Figure 28 Indicative Pricing Analysis for Biosimulation Software
Figure 29 Influence of Stakeholders on Buying Process of Top 3 End-users
Figure 30 Key Buying Criteria for Top 3 End-users
Figure 31 Trends & Disruptions Impacting Customers’ Businesses
Figure 32 Biosimulation Market: Investment & Funding Scenario
Figure 33 Market Potential of AI/Generative AI on Biosimulation
Figure 34 Impact of AI/Gen AI on Interconnected and Adjacent Ecosystems
Figure 35 North America: Biosimulation Market Snapshot
Figure 36 Asia-Pacific: Biosimulation Market Snapshot
Figure 37 Revenue Analysis of Key Players in Biosimulation Market, 2019-2023 (USD Billion)
Figure 38 Biosimulation Market: Market Share Analysis (2023)
Figure 39 Ranking of Key Players in Biosimulation Market, 2023
Figure 40 Biosimulation Market: Company Evaluation Matrix (Key Players), 2023
Figure 41 Biosimulation Market: Company Footprint
Figure 42 Biosimulation Market: Company Evaluation Matrix (Start-Ups/SMEs), 2023
Figure 43 EV/EBITDA of Key Vendors
Figure 44 Year-to-Date (YTD) Price Total Return and 5-Year Stock Beta of Biosimulation Vendors
Figure 45 Biosimulation Market: Brand/Product Comparative Analysis
Figure 46 Certara, USA: Company Snapshot (2023)
Figure 47 Dassault Systèmes: Company Snapshot (2023)
Figure 48 Schrödinger, Inc.: Company Snapshot (2023)
Figure 49 Simulations Plus: Company Snapshot (2023)
Figure 50 Genedata AG (A Danaher Company): Company Snapshot (2023)
Figure 51 Physiomics PLC: Company Snapshot (2023)
Figure 52 Openeye, Cadence Molecular Sciences: Company Snapshot (2023)
Figure 53 Ansys, Inc.: Company Snapshot (2023)